First look at the five-factor model personality facet associations with sensory processing sensitivity

status: publishe

Hoogsensitiviteit: over orchideeën, paardenbloemen en wellicht ook tulpen

Hoogsensitiviteit is een populair begrip in boeken voor een breed publiek, CLB, school en hulpverlening. Hoewel hoogsensitiviteit diverse invullingen kent en er verschillende meningen over bestaan, staat het wetenschappelijk onderzoek naar hoogsensitiviteit nog in zijn kinderschoenen. In dit artikel krijg je een stand van zaken van dat wetenschappelijk onderzoek. Wat weten we al over hoogsensitiviteit en wat weten we nog niet?status: publishe

Environmental Sensitivity as a moderator in the relation between parenting and children’s emotional problems, behavioral problems, and functioning at school

status: publishe

Methylation in Development -MIND

This study is longitudinal project in which 599 fifth graders (Mage= 10.76, SDage= 0.48, boys= 44%) and their parents participated at Wave 1 (March 2017- mid January 2018) and were followed for three years (end of data collection: January 2020). In all three waves, questionnaire data measuring Environmental Sensitivity, depressive symptoms, externalizing problems, temperament, personality, parenting, emotional and social wellbeing, daily hassles, major life events, and friendship quality from self and parent reports are assessed. Additionally, in each wave we collected saliva samples for DNA extraction. The children also completed the Middle Childhood Attachment Script Assessment interview at each wave. In the second wave, physiological data related to stress-reactivity (i.e., cortisol samples, heart rate variability, and skin conductance level) were collected in a random subsample (n=101) under standardized laboratory conditions

Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples

BACKGROUND: Testing for KRAS mutations in metastatic colorectal cancer (mCRC) on formalin-fixed, paraffin embedded (FFPE) tumor tissue has become standard of care. Different molecular methods exist to determine hotspot KRAS mutations in exon 2, 3 and 4, but testing is often limited by the sensitivity and the speed of analysis. The aim of this retrospective study was to establish the clinical performance of the Idylla™ KRAS Mutation Test on FFPE tumor samples of patients with mCRC. METHODS: KRAS mutation analysis was performed using the therascreen KRAS on the RotorGene Q platform (CE-IVD; Qiagen) and results were subsequently compared to the Idylla™ KRAS Mutation Test. Discordant result testing was performed with massive parallel sequencing or alternative routine approaches. RESULTS: Data from 182 samples were used to show that the overall agreement between the two methods for mutation characterization was 96.7% [95%CI: 93.0%-98.5%]. Six out of 182 samples (3.3%) showed true discordant results. CONCLUSION: The Idylla™ KRAS Mutation Test allows for a fast and reliable analysis of FFPE samples with a turnaround-time of two hours without the need of molecular infrastructure or expertise in order to guide the personalized treatment of colorectal cancer patients

The Highly Sensitive Child scale 24 item version and its relation to children’s and adolescents’ functioning in school context

status: publishe

Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer.

The complexity of delivering precision medicine to oncology patients has led to the creation of molecular tumourboards (MTBs) for patient selection and assessment of treatment options. New technologies like the liquid biopsy are augmenting available therapeutic opportunities. This report aims to analyse the experience of our MTB in the implementation of personalised medicine in a cancer network.info:eu-repo/semantics/publishe

Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer

Background: The complexity of delivering precision medicine to oncology patients has led to the creation of molecular tumourboards (MTBs) for patient selection and assessment of treatment options. New technologies like the liquid biopsy are augmenting available therapeutic opportunities. This report aims to analyse the experience of our MTB in the implementation of personalised medicine in a cancer network. Materials and methods: Patients diagnosed with solid tumours progressing to standard treatments were referred to our Phase I unit. They underwent comprehensive next generation sequencing (NGS) of either tumour tissue or cell-free circulating tumour DNA (ctDNA) or both. The MTB expressed either a positive or negative opinion for the treatment of the patients with discovered druggable alterations inside a clinical trial, in an expanded access programme, with a compassionate use. Afterwards, discovered alterations were matched with OncoKB levels of evidence for the choice of alteration-specific treatments in order to compare MTB outcomes with a standardised set of recommendations. Results: NGS was performed either on ctDNA or tumour tissue or in both of them in 204 patients. The MTB evaluated 173 of these cases. Overall, the MTB proposed alteration-specific targeted therapy to 72 patients (41.6%). 49 patients (28.3% of the total evaluated) were indicated to enter a clinical trial. In 29 patients with matched liquid biopsy NGS (lbNGS), tumour tissue NGS (ttNGS) and MTB evaluation, the MTB changed the treatment strategy coming from standardised recommendations based on lbNGS and ttNGS alone in 10 patients (34.5%), thanks to the evaluation of other clinical parameters. In our cohort, lbNGS was more likely, compared with ttNGS, to detect point mutations (OR 11, 95% CI 2.9 to 24.1, p<0.001) and all-type alterations (OR 13.6, 95% CI 5.5 to 43.2, p<0.001) from the same genes of matched patients. Conclusions: Our MTB allows patients with refractory cancer to be included in clinical trials and improves the precision of clinical decisions compared with a standardised set of mutation-driven recommendations.status: publishe